Your Article Summary
See Latest ArticlesAmgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
Amgen, 06/23/09
Amgen Inc. announced that the U.S. Food and Drug Administration has asked the company to participate in a meeting of the Reproductive Health Drugs Advisory Committee on Aug. 2009. The RHDAC will review data supporting the Biologics License Application for denosumab, a RANK Ligand inhibitor for which Amgen is seeking approval for prevention and treatment of postmenopausal osteoporosis and prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate or breast cancer.
Today in Conferences/Meetings...keeping you current
Receive free subspecialty "5-minute updates" via email
Covidien plc to Report First-Quarter Results on January 2010
Covidien, 12/17/09
MediGene AG presents future business plan at annual analyst conference
MediGene, 12/16/09
Summit to Tackle Rural Health I.T.
HealthDataManagement, 12/16/09